The randomized-controlled trial is widely accepted as a clinical trial to decide a standard therapy. It remains to be concluded whether or not patients benefit from participation itself in a randomized-controlled trial. This study was aimed at comparing prognoses between trial participants and participation-refusers. Concerned randomized trials are 'selection of effective chemotherapy for breast cancer' (SELECT BC) and its successor trial, SELECT BC-CONFIRM. Study subjects are all of metastatic breast cancer patients who are requested by their doctors to participate in these two trials. This trial is a hitherto exceptional prospective study and is suitable to clarify the effects of participation per se in such a trial on prognosis when compared with previous two studies.
INTRODUCTION
At the present time, the randomized-controlled trial is a widely accepted procedure to establish a standard therapy.
In 1985, Davis et al.
(1) compared participants and nonparticipants in a randomized-controlled trial in postoperative non-small cell lung cancer patients, reporting a significantly better survival in the trial participants. Similarly, as reported in 2000 by Gnant (2) , participants in nine randomizedcontrolled trials showed a longer overall survival than nonparticipants among patients with Stage I or II early breast cancer.
Therefore, participation itself has the potential to improve patients' prognoses in the randomized-controlled trial. On the other hand, Peppercorn et al. (3) reviewed 26 reports on comparison of clinical trial participants and non-participants, concluding that there was no evidence enough to definitely favor the prognosis of the participants. Furthermore, in 2009, a similar comparative study was performed by Tanai et al. in Japanese advanced lung cancer patients. These investigators found no significant difference in prognosis between participants and non-participants in a randomized-controlled trial (4). As mentioned above, it has not been concluded yet whether or not participation per se in a randomized-controlled trial provides a better prognosis to patients. If non-participants include patients who are in such a bad condition that they do not meet entry criteria of a trial, non-participants have logically worse prognoses. Additionally, a trial may have the following effects and biases: effects of protocol therapy per se, care effects, Horson effects and placebo effects; and patient selection biases, clinical doctor selection biases and movement biases (5) . Unless these biases are well controlled and minimized, it cannot be clarified whether or not participation per se in a randomized-controlled trial benefits participants. This is an accompanying study of 'selection of effective chemotherapy for breast cancer' (SELECT BC) and its successor, SELECT BC-CONFIRM (6) . The SELECT BC and SELECT BC-CONFIRM trials are one of the largest scale randomized-controlled trials that are now ongoing in Japan in metastatic or recurrent breast cancer patients (Fig. 1) .
This study has been designed so that study subjects are all patients who meet the eligibility criteria of SELECT BC as well as SELECT BC-CONFIRM trials and are requested for participation by attending doctors to compare prognoses between participants and participation-refusers. Since therapeutic agents that are to be administered to participants in both trials have been already approved, it is expected that participants and participation-refusers receive almost identical therapy except for orders of agent administration.
Treatment methods, examinations to be performed during therapy and observation methods of participants of both trials take a practical approach, and so care seems to be scarcely different in its effects between both trials. It is also expected that backgrounds of the participants and participation-refusers are eventually similar, because study subjects have to meet the eligibility criteria of both trials and are free to participate or refuse. Accordingly, this study is more suitable for clarifying effects of participation itself in randomized-controlled trials on prognosis than previous studies. Moreover, this study is a rare prospective study of great significance.
DIGEST OF THE STUDY PROTOCOL

PURPOSE
To prospectively perform a prognostic study of participants and participation-refusers of SELECT BC and SELECT BC-CONFIRM trials to compare their life prognoses.
RESOURCES This study was funded by Comprehensive Support Project for Oncology Research (CSPOR) of Public Health Research
Foundation. The research fund was provided to CSPOR by Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical took no part in this study other than providing information relevant to proper use of the study drug. All decisions concerning the planning, implementation and publication of this study were made by the executive committee of this study.
ENDPOINT
The endpoint is overall survival.
ELIGIBILITY CRITERIA
All patients that were proposed to participate in SELECT BC and SELECT BC-CONFIRM trials are study subjects of SELECT BC ECO. A participation-refuser is defined as 'a person who meets the eligibility criteria of SELECT BC and SELECT BC-CONFIRM but refuses to participate on their own will'. The inclusion and exclusion criteria of both trials are described below. 
TREATMENT
TAXANE ARM
For the taxane arm, one of the three regimens described below will be selected. Before the start of treatment, the treatment regimen will be selected at the discretion of the investigator. The same regimen will be used for the duration of first-line treatment. The reason for selecting the regimen will be reported in the 'Follow-up Report'.
(i) Docetaxel 60 -75 mg/m 2 administered at 3-or 4-week intervals. Treatment will be repeated until tumor progression or for at least six courses (18 or 24 weeks).
(ii) Paclitaxel 175 mg/m 2 administered at 3-or 4-week intervals. Treatment will be repeated until tumor progression or for at least six courses (18 or 24 weeks). (iii) Paclitaxel 80 -100 mg/m 2 administered every week. Weekly treatment for three consecutive weeks, followed by a 1-week rest period will comprise one course. Treatment will be repeated until tumor progression or for at least six courses (24 weeks).
ANTHRACYCLINE ARM
One of the following regimens will be selected at the discretion of the attending physician, and treatment will be repeated until disease progression or for at least six courses. Cyclophosphamide 500 mg/m 2 þ given at 3-or 4-week intervals.
TS-1 ARM
TS-1 will be administered orally in doses of 40 -60 mg twice daily for 28 consecutive days. The dose will be assigned according to body weight. Treatment will be followed by a 14-day rest period to complete one course. Treatment will be repeated until tumor progression or for at least four courses (24 weeks).
Participating doctors must send each patient's information to the CSPOR Data Center for registering patients to this study. Detailed information, for example, why patients refused to participate in the original clinical trial 'SELECT-BC, SELECT-BC CONFIRM', will be gathered afterward with a submitted Case Report Form. This study has been ongoing completely in parallel with the original prospective study.
Treatment methods for participation-refusers are not defined.
PERIOD OF THIS STUDY
This study ends when both SELECT BC and SELECT BC-CONFIRM trials end.
STATISTICAL ANALYSIS
Ratios of participants to participation-refusers in this study are assumed to fall between 1 to 2 and 2 to 1. Two groups of participants and refusers are examined by the Kaplan -Meier method for cumulative survival rates. In addition, the log -log plot is applied to Kaplan -Meier curves of both groups to confirm inter-group proportionality of hazards.
In both SELECT BC and SELECT BC-CONFIRM trials, the following items are used as allocation adjustment factors: (1) institution, (2) the presence or absence of liver metastasis, (3) the presence or absence of hormone sensitivity, (4) administration or non-administration of taxanes, (5) oral administration or non-administration of 5-FU agents and (6) period from surgery to recurrence. If there is a significant difference in these allocation adjustment factors in comparison of the two groups, adjustment is made before the analysis.
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